Skip to content
20-F/A

Annual Report (Foreign)

INTELLIPHARMACEUTICS INTERNATIONAL INC.

0001654954-24-001327

← back to feed
Filed
Feb 6, 2024 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Jun 10, 2023 33.09M sh
Capex FY 2023 · Nov 30, 2022 $0
Capex FY 2023 · Nov 30, 2021 $0
Capex FY 2023 · Nov 30, 2020 $3.88K
Operating Cash Flow FY 2023 · Nov 30, 2022 −$1.39M
Operating Cash Flow FY 2023 · Nov 30, 2021 −$2.46M
Operating Cash Flow FY 2023 · Nov 30, 2020 $112.11K
Cash And Equivalents FY 2023 · Nov 30, 2022 $83.72K
Cash And Equivalents FY 2023 · Nov 30, 2021 $771.95K
Stockholders Equity FY 2023 · Nov 30, 2022 −$10.58M
Stockholders Equity FY 2023 · Nov 30, 2021 −$8.16M
Stockholders Equity FY 2023 · Nov 30, 2020 −$6.31M
Stockholders Equity FY 2023 · Nov 30, 2019 −$3.69M
Total Liabilities FY 2023 · Nov 30, 2022 $12.01M
Total Liabilities FY 2023 · Nov 30, 2021 $10.25M
Current Assets FY 2023 · Nov 30, 2022 $492.51K
Current Assets FY 2023 · Nov 30, 2021 $1.1M
Total Assets FY 2023 · Nov 30, 2022 $1.43M
Total Assets FY 2023 · Nov 30, 2021 $2.1M
Sga Expense FY 2023 · Nov 30, 2022 $561.05K
Sga Expense FY 2023 · Nov 30, 2021 $1.25M
Sga Expense FY 2023 · Nov 30, 2020 $2.15M
Rd Expense FY 2023 · Nov 30, 2022 $2.15M
Rd Expense FY 2023 · Nov 30, 2021 $2.66M
Rd Expense FY 2023 · Nov 30, 2020 $3.52M
Net Income FY 2023 · Nov 30, 2022 −$2.89M
Net Income FY 2023 · Nov 30, 2021 −$5.15M
Net Income FY 2023 · Nov 30, 2020 −$3.39M
Operating Income FY 2023 · Nov 30, 2022 −$2.85M
Operating Income FY 2023 · Nov 30, 2021 −$4.17M
Operating Income FY 2023 · Nov 30, 2020 −$4.68M
Revenue FY 2023 · Nov 30, 2022 $65.73K
Revenue FY 2023 · Nov 30, 2021 $0
Revenue FY 2023 · Nov 30, 2020 $1.4M